{"doi":"10.1111/tan.15715","title":"Analysis of <scp><i>KIR</i></scp> and <scp><i>HLA</i></scp> Polymorphism in Chinese Individuals With <scp>COVID</scp>‐19","abstract":"ABSTRACT Killer‐cell immunoglobulin‐like receptor (KIR) interactions with HLA class I have crucial roles in modulating NK cell function in response to viral infections. To explore the correlation between KIR/HLA and susceptibility to SARS‐CoV‐2 infection, we analysed polymorphism of KIR genes, haplotypes, HLA allotypes, and the interplay between KIR and HLA in individuals diagnosed with COVID‐19. Compared to a population control group, we observed a significantly increased frequency of KIR3DL3*00802 in the COVID‐19 group. When encoded by the HLA‐B gene, the frequency of HLA‐Bw4, a ligand for KIR3DL1, was at lower frequency in the COVID‐19 group. Additionally, significantly elevated frequencies of KIR‐Bx3 , KIR3DL3*00301 , 3DL3*048 , and C1 + HLA‐C were identified in the COVID‐19 group before multiple test correction, suggesting associations with susceptibility to SARS‐CoV‐2 infection. Our findings indicate that the KIR3DL3*00802 allele may be a high‐risk factor for SARS‐CoV‐2 infection, while Bw4 encoded by HLA‐B gene may confer protective effects against the infection.","journal":"HLA","year":2024,"id":481691,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":1,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.949,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2024-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1317715,"name":"Xuan You","orcid":null,"position":1,"is_corresponding":false},{"id":19722,"name":"Paul J. Norman","orcid":"0000-0001-8370-7703","position":2,"is_corresponding":false},{"id":774981,"name":"Katherine M. Kichula","orcid":"0000-0002-9817-3043","position":3,"is_corresponding":false},{"id":1317414,"name":"Lina Dong","orcid":"0000-0002-6791-7871","position":4,"is_corresponding":false},{"id":1317415,"name":"Nanying Chen","orcid":"0000-0002-1589-5893","position":5,"is_corresponding":false},{"id":774983,"name":"Ji He","orcid":"0009-0000-4135-3732","position":6,"is_corresponding":false},{"id":1317417,"name":"Wei Zhang","orcid":"0000-0002-7341-690X","position":7,"is_corresponding":false},{"id":774984,"name":"Faming Zhu","orcid":"0000-0002-1963-9176","position":8,"is_corresponding":false},{"id":505835,"name":"Sudan Tao","orcid":null,"position":0,"is_corresponding":true}],"reference_count":52,"raw_metadata":null,"created_at":"2026-07-19T02:07:10.067421Z","pmid":"39364548","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}